DEF 14A: Acrivon Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Acrivon Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, featuring the election of Class II directors and ratification of the independent auditor.

Summary

• Acrivon Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, at 11:00 a.m. Eastern Time.
• Stockholders will vote on the election of three Class II director nominees: Kristina Masson, Sharon Shacham, and Ivana Magovevi-Liebisch, each for a three-year term expiring in 2027.
• The meeting will also include a vote to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors encourages stockholders to review the proxy statement and cast their votes promptly.
• The record date for determining stockholders eligible to vote is April 22, 2024.
• As of the record date, there were 30,875,456 shares of common stock issued, outstanding, and entitled to vote.
• The company is taking advantage of SEC rules to furnish proxy materials via the Internet, reducing environmental impact and costs.
• The Notice of Annual Meeting, Proxy Statement, and Annual Report on Form 10-K for the fiscal year ended December 31, 2023, are available online.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the company's commitment to good governance and the use of technology to enhance stockholder participation. The mention of a recent private placement is a positive sign of investor confidence.

Positives

• The company is embracing technology by holding a virtual annual meeting, potentially increasing stockholder participation.
• Online distribution of proxy materials reduces environmental impact and lowers costs.
• The Board is recommending experienced candidates for election as Class II directors.
• The Audit Committee recommends the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm.

Risks

• If stockholders fail to ratify the appointment of PricewaterhouseCoopers LLP, the audit committee will reconsider the appointment, but may still retain PwC.
• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our company.

Future Outlook

The Board is not aware of any other matters to be considered at the Annual Meeting other than those described in the Notice.

Management Comments

• Peter Blume-Jensen, M.D., Ph.D., Chief Executive Officer, President and Chairman of the Board: 'We are pleased to invite you to join us for the 2024 Annual Meeting of Stockholders of Acrivon Therapeutics, Inc.'
• Peter Blume-Jensen, M.D., Ph.D., Chief Executive Officer, President and Chairman of the Board: 'Our Board of Directors is committed to governance practices that are appropriately tailored to our business and to guiding Acrivon to deliver on our commitment to developing precision medicines to improve the lives of patients.'
• Peter Blume-Jensen, M.D., Ph.D., Chief Executive Officer, President and Chairman of the Board: 'On behalf of the Board of Directors and the Acrivon team, we would like to thank you for your continued support.'

Industry Context

This proxy statement is a standard document for publicly traded companies, outlining the matters to be voted on at the annual meeting and providing information about the company's governance and executive compensation. The virtual meeting format reflects a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation policy is consistent with market practices for newly public biotechnology companies.
• The company's corporate governance guidelines and committee charters align with Nasdaq and SEC requirements.
• The use of a virtual annual meeting is becoming increasingly common among public companies to improve accessibility and reduce costs.
• The company's related person transaction policy adheres to Item 404 of Regulation S-K, a standard practice for public companies.

Management Changes

Related Party Transactions

• In November 2022, Acrivon completed a private placement in which it issued and sold 400,000 shares of its common stock at $12.50 per share to Chione Limited.
• On April 8, 2024, Acrivon entered into a securities purchase agreement for a private placement with certain institutional and accredited investors, including RA Capital Healthcare Fund, L.P., Perceptive Life Sciences Master Fund, Ltd., Sands Capital Life Sciences Pulse Fund II, L.P., and Citadel CEMF Investments Ltd.

Stakeholder Impact

• Stockholders have the opportunity to vote on key matters affecting the company's governance and direction.
• Employees are indirectly impacted by the decisions made at the Annual Meeting, particularly regarding the election of directors and the ratification of the auditor.
• The outcome of the votes could influence investor confidence and the company's ability to attract future investment.

Next Steps

• Stockholders should review the proxy materials and cast their votes before the June 20, 2024 deadline.
• The company will hold the Annual Meeting on June 20, 2024, to conduct the outlined business.
• The company will file a registration statement with the SEC covering the resale of shares issued in the recent private placement by May 11, 2024.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Acrivon Therapeutics, PricewaterhouseCoopers, Auditor, Election, Ratification, Governance